NewslettersExtracellular Matrix NewsHepatic Cell NewsTransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat CholangiocarcinomaBy Justin.choi - November 9, 2021010TransThera Sciences Inc. announced that the US FDA has granted Fast Track Designation to its Phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinom who have no standard treatment options.[TransThera Sciences] 7992332 {7992332:nan} apa 50 1 168731 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release